Smashed Peaches

Drug Research Studies

Ayahuasca inspires another biotech startup at ATAI; Mylan TB drug gets green light in India – Endpoints News

→ We have one more start­up to add to the list be­fore we call it a day. ATAI Life Sci­ences, which likes to dab­ble with psy­che­delics in de­vel­op­ing new ther­a­pies, has an­oth­er mind ben­der in the works. They’ve kick­start­ed a new com­pa­ny to delve in­to  for­mu­la­tions of N,N-di­methyl­trypt­a­mine (DMT) —the ac­tive in­gre­di­ent in ayahuas­ca — for new drugs to use in the men­tal health field. DMT acts as a par­tial ag­o­nist on a va­ri­ety of 5-HT re­cep­tors, they say, which makes it a good can­di­date for pa­tients not at­tract­ed to the po­tent brew fea­tured on cer­tain South Amer­i­can jour­neys. “These nov­el prod­ucts are ex­pect­ed to sim­pli­fy in-clin­ic ad­min­is­tra­tion and al­low greater phar­ma­co­ki­net­ic con­trol of the psy­che­del­ic ex­pe­ri­ence and its over­all du­ra­tion,” said Srini­vas Rao, chief sci­en­tif­ic of­fi­cer of ATAI. “Pa­tients may even be able to at­tend psy­chother­a­py ses­sions lat­er the same day.”

My­lan has re­ceived the green light from reg­u­la­tors in In­dia for its tu­ber­cu­lo­sis drug pre­tomanid. It’s on­ly the third treat­ment for drug-re­sis­tant forms of the dis­ease to be ap­proved in more than 40 years, fol­low­ing J&J’s be­daquiline and Ot­su­ka’s de­la­manid. In­dia ac­counts for rough­ly 25% of the world’s tu­ber­cu­lo­sis cas­es, and Covid-19 has raised fears that pre­vi­ous ef­forts to cur­tail TB will be ham­pered. The WHO said in May that an ad­di­tion­al 1.4 mil­lion peo­ple could die from TB with­in the next five years as a di­rect re­sult of the Covid-19 pan­dem­ic.

→ The Alzheimer’s Drug Dis­cov­ery Foun­da­tion has sealed sev­er­al part­ner­ships with Roche, Sh­iono­gi, J&J’s Janssen and Ei­sai to launch a biobank shar­ing pro­gram. Part of the Di­ag­nos­tics Ac­cel­er­a­tor, the ini­tia­tive aims to de­vel­op bet­ter bio­mark­er tests by an­a­lyz­ing blood and cere­bral spinal flu­id spec­i­mens from Alzheimer’s pa­tients in ear­li­er clin­i­cal tri­als.

The Ohio State Uni­ver­si­ty has spun a com­pa­ny out of Zhi­wei Hu’s lab, pro­vid­ing the seed fund­ing to run more pre­clin­i­cal stud­ies and scale up man­u­fac­tur­ing for his next-gen­er­a­tion tis­sue fac­tor (TF) im­munother­a­pies tar­get­ing triple-neg­a­tive breast can­cer, among oth­ers. Cin­cyTech, a lo­cal fund in Cincin­nati, led the fi­nanc­ing for Eikonok­lastes Ther­a­peu­tics, which is run by for­mer My­onexus ex­ec Bruce Hal­pryn.